» Articles » PMID: 19046847

A Nomogram Predictive of Non-sentinel Lymph Node Involvement in Breast Cancer Patients with a Sentinel Lymph Node Micrometastasis

Overview
Publisher Elsevier
Date 2008 Dec 3
PMID 19046847
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Predictive factors of non-sentinel lymph node (NSN) involvement at axillary lymph node dissection (ALND) have been studied in the case of sentinel node (SN) involvement, with validation of a nomogram. This nomogram is not accurate for SN micrometastasis. The purpose of our study was to determine a nomogram for predicting the likelihood of NSN involvement in breast cancer patients with a SN micrometastasis.

Methods: We collated 909 observations of SN micrometastases with additional ALND. Characteristics of the patients, tumours and SN were analysed.

Results: Involvement of SN was diagnosed 490 times (53.9%) with standard staining (HES) and 419 times solely on immunohistochemical analysis (IHC) (46.1%). NSN invasion was observed in 114 patients (12.5%), whereas 62.3% (71) had only one NSN involved and 37.7% (43) two or more NSN involved. In multivariate analysis, significant predictive factors were: tumour size (pT stage < or = 10 mm or >11 and < or = 20 or >20 mm [odds ratio (OR) 2.1 and 3.43], micrometastases detected by HES or IHC [OR 1.64], presence or absence of lymphovascular invasion (LVI) [OR 1.76], tumour histological type mixed or not [OR 2.64]. The rate and probability of NSN involvement with the model are given for 24 groups, with a representation by a nomogram.

Conclusion: One group, corresponding to 10.1% of the patients, was associated with a risk of NSN involvement of less than 5%, and five groups, corresponding to 29.8% of the patients, were associated with a risk < or = 10%. Omission of ALND could be proposed with minimal risk for a low probability of NSN involvement.

Citing Articles

Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or Micrometastases.

Houvenaeghel G, Heinemann M, Classe J, Bouteille C, Gimbergues P, Azuar A Cancers (Basel). 2024; 16(15).

PMID: 39123393 PMC: 11312260. DOI: 10.3390/cancers16152666.


Optimal therapeutic strategy for non-small cell lung cancer with thoracic extrathoracic metastasis: a study based on SEER database.

He Z, Sun X, Xu J, Wang L, Cheng J, Lv W J Thorac Dis. 2024; 16(2):1021-1033.

PMID: 38505038 PMC: 10944759. DOI: 10.21037/jtd-23-516.


The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.

Houvenaeghel G, de Nonneville A, Chopin N, Classe J, Mazouni C, Chauvet M Cancer Med. 2022; 12(4):4023-4032.

PMID: 36127853 PMC: 9972015. DOI: 10.1002/cam4.5257.


Development of a prediction model based on LASSO regression to evaluate the risk of non-sentinel lymph node metastasis in Chinese breast cancer patients with 1-2 positive sentinel lymph nodes.

Meng L, Zheng T, Wang Y, Li Z, Xiao Q, He J Sci Rep. 2021; 11(1):19972.

PMID: 34620978 PMC: 8497590. DOI: 10.1038/s41598-021-99522-3.


The Sentinel Lymph Node in Breast Cancer: Problems Posed by Examination During Surgery. A Review of Current Literature and Management.

de Joliniere J, Major A, Khomsi F, Ben Ali N, Guillou L, Feki A Front Surg. 2018; 5:56.

PMID: 30488035 PMC: 6247078. DOI: 10.3389/fsurg.2018.00056.